Multicenter Study on the Safety and Efficacy of First-Line Nivolumab-Combination Chemotherapy in Patients Aged 75 Years and Older with Unresectable Advanced or Recurrent Gastric Cancer.

Introduction: Nivolumab combined with chemotherapy has been approved as the first-line treatment for HER2-negative, unresectable, advanced, or recurrent gastric cancer. Patients aged ≥75 years have impaired organ function and comorbidities that increase the risk of adverse events, including immune-r...

Descripción completa

Detalles Bibliográficos

Publicado en:	Oncology Vol. 104; no. 8; pp. 872 - 880
Autores principales:	Kimura, Akiharu, Sano, Akihiko, Nakazawa, Nobuhiro, Kumakura, Yuji, Yamashita, Toshiki, Tanaka, Naritaka, Saito, Kana, Ogata, Kyoichi, Kasuga, Kengo, Nakazato, Kenji, Yoshinari, Daisuke, Shimizu, Hisashi, Ubukata, Yasunari, Hosaka, Hisashi, Okada, Takuhisa, Shiraishi, Takuya, Sakai, Makoto, Shirabe, Ken, Saeki, Hiroshi
Formato:	research tables/charts Journal Article
Publicado:	Karger AG 2026
Acceso en línea:	Ver este registro en EBSCOhost